BENEFIT FROM ANTI-EGFR THERAPY IN KRAS, BRAF, NRAS, PI3KCA "ALL WILD TYPE", EGFR POSITIVE COLORECTAL CANCER PATIENTS.

被引：0
|
作者：
De Maglio, Giovanna [1 ]
Aprile, Giuseppe [2 ]
Foltran, Luisa [2 ]
Masiero, Elena [1 ]
Lutrino, Stefania [2 ]
Cardellino, Giovanni [2 ]
Fontanella, Caterina [2 ]
Fasola, Gianpiero [2 ]
Pizzolitto, Stefano [1 ]
机构：
[1] Univ Hosp, Dept Pathol, Udine, Italy
[2] Univ Hosp, Dept Oncol, Udine, Italy
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：v107 / v107
页数：1
相关论文
共 50 条
  • [41] Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
    Wang, Chongkai
    Sandhu, Jaideep
    Fakih, Marwan
    ONCOLOGIST, 2022, 27 (02): : 104 - 109
  • [42] The Role of Focal Adhesion Kinase (FAK) in Response to Anti-EGFR Therapy in KRAS Wild-Type Colorectal Cancers
    Carvalho, B.
    Tijssen, M.
    de Groen, F. L. M.
    Postma, C.
    Meijer, G. A.
    JOURNAL OF PATHOLOGY, 2013, 229 : S22 - S22
  • [43] The occurrence of mutant KRAS clones in the blood of RAS wild type colorectal cancer patients: Impact of response or failure under anti-EGFR therapy.
    Berger, Andreas W.
    Schwerdel, Daniel
    Welz, Hanna
    Ettrich, Thomas Jens
    Moeller, Peter
    Seufferlein, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [44] Thoracic Cytological Specimens Obtained In Routine Clinical Practice And EGFR, Kras, Her2, Braf And Pi3kca Mutation Status In Metastatic Cancer Patients
    Vandemoortele, T.
    Nanni-Metellus, I.
    Kaspi, E.
    Secq, V.
    Laroumagne, S.
    Roll, P.
    Roca, E.
    Dutau, H.
    Robaglia-Schlupp, A.
    Astoul, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [45] ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
    Segelov, Eva
    Waring, Paul
    Desai, Jayesh
    Wilson, Kate
    Gebski, Val
    Thavaneswaran, Subotheni
    Elez, Elena
    Underhill, Craig
    Pavlakis, Nick
    Chantrill, Lorraine
    Nott, Louise
    Jefford, Michael
    Khasraw, Mustafa
    Day, Fiona
    Wasan, Harpreet
    Ciardiello, Fortunato
    Karapetis, Chris
    Joubert, Warren
    van Hazel, Guy
    Haydon, Andrew
    Price, Tim
    Tejpar, Sabine
    Tebbutt, Niall
    Shapiro, Jeremy
    BMC CANCER, 2016, 16
  • [46] ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
    Eva Segelov
    Paul Waring
    Jayesh Desai
    Kate Wilson
    Val Gebski
    Subotheni Thavaneswaran
    Elena Elez
    Craig Underhill
    Nick Pavlakis
    Lorraine Chantrill
    Louise Nott
    Michael Jefford
    Mustafa Khasraw
    Fiona Day
    Harpreet Wasan
    Fortunato Ciardiello
    Chris Karapetis
    Warren Joubert
    Guy van Hazel
    Andrew Haydon
    Tim Price
    Sabine Tejpar
    Niall Tebbutt
    Jeremy Shapiro
    BMC Cancer, 16
  • [47] EGFR gene copy number to predict response to anti-EGFR treatment and survival in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer
    Carpen, Olli
    Algars, Annika
    Sundstrom, Jari
    Kytola, Soili
    Osterlund, Pia
    Lintunen, Minnamaija
    Jokilehto, Terhi
    Kaare, Milja
    Orpana, Arto
    Vainionpaa, Reetta
    Ristimaki, Ari
    Ristamaki, Raija
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients
    Bonin, Serena
    Donada, Marisa
    Bussolati, Gianni
    Nardon, Ermanno
    Annaratone, Laura
    Pichler, Martin
    Chiaravalli, Anna Maria
    Capella, Carlo
    Hoefler, Gerald
    Stanta, Giorgio
    TUMOR BIOLOGY, 2016, 37 (06) : 7295 - 7303
  • [49] No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?
    Sunakawa, Y.
    Tsuji, A.
    Fujii, M.
    Ichikawa, W.
    ANNALS OF ONCOLOGY, 2017, 28 (08) : 2030 - 2031
  • [50] Response to BRAF inhibitors combined with anti-EGFR after previous anti-EGFR exposure for BRAF V600E mutant metastatic colorectal cancer patients
    Hafliger, E.
    Boccaccino, A.
    El-Khoury, R.
    Perret, A.
    Pietrantonio, F.
    Pilla, L.
    Lecomte, T.
    Scartozzi, M.
    Soularue, E.
    Salvatore, L.
    Bourgeois, V.
    Salati, M.
    Vaillant, J. N.
    Gallois, C.
    Lonardi, S.
    Cremolini, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S554 - S554
12345